TG Therapeutics (NASDAQ:TGTX) Shares Gap Up – Here’s What Happened

Shares of TG Therapeutics, Inc. (NASDAQ:TGTX) gapped up before the market opened on Wednesday . The stock had previously closed at $27.87, but opened at $31.16. TG Therapeutics shares last traded at $30.20, with a volume of 2,367,283 shares trading hands.

More TG Therapeutics News

Here are the key news stories impacting TG Therapeutics this week:

• Positive Sentiment: Seeking Alpha published an upgrade/positive piece that highlights accelerating commercial momentum and investor “exit velocity,” supporting a more bullish growth narrative for TG Therapeutics. TG Therapeutics: The ‘Exit Velocity’ You Can’t Ignore (Rating Upgrade)
• Positive Sentiment: Media reported that Goldman Sachs sees substantial upside (~32% rally potential) as Briumvi sales accelerate, which supports a bullish case for continued revenue and earnings upside. TG Therapeutics stock pops as Briumvi boom reignites bull case: Goldman Sachs sees room for 32% rally
• Positive Sentiment: HC Wainwright raised its Q4 2025 EPS estimate to $0.27 (from $0.20) and keeps a “Buy” rating with a $60 target — a clear near‑term analyst endorsement that can support upside. MarketBeat TGTX analyst note
• Positive Sentiment: HC Wainwright also raised FY2025 EPS to $2.89 (from $2.83), reflecting stronger near‑term earnings expectations tied to current product momentum. MarketBeat TGTX analyst note
• Neutral Sentiment: HC Wainwright published a set of long‑range forecasts (FY2026–FY2030, including FY2030 EPS of $3.96). These long‑horizon numbers frame upside potential but are model‑dependent and less immediately market‑moving. MarketBeat TGTX analyst note
• Negative Sentiment: Bank of America Securities initiated/maintained a “Sell” on TGTX, which is directly bearish and likely pressured the stock amid mixed optimism elsewhere. TG Therapeutics (TGTX) Receives a Sell from Bank of America Securities
• Negative Sentiment: HC Wainwright trimmed several mid‑to‑longer‑term estimates (Q4 2026, FY2026–FY2029, FY2028–FY2029 down slightly), signaling some moderation in the firm’s prior growth assumptions and reducing upside in those years despite the persistent $60 target. MarketBeat TGTX analyst note

Wall Street Analysts Forecast Growth

TGTX has been the topic of a number of analyst reports. Weiss Ratings reiterated a “hold (c+)” rating on shares of TG Therapeutics in a report on Monday, December 29th. The Goldman Sachs Group lifted their target price on TG Therapeutics from $37.00 to $39.00 and gave the company a “neutral” rating in a research note on Thursday. B. Riley upgraded shares of TG Therapeutics to a “strong-buy” rating in a report on Tuesday, November 4th. JPMorgan Chase & Co. lifted their price objective on shares of TG Therapeutics from $46.00 to $49.00 and gave the stock an “overweight” rating in a research report on Monday, November 3rd. Finally, Wall Street Zen raised shares of TG Therapeutics from a “hold” rating to a “buy” rating in a research report on Sunday, December 14th. One equities research analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating and two have issued a Hold rating to the company’s stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $50.75.

TG Therapeutics Stock Performance

The company has a current ratio of 3.82, a quick ratio of 2.89 and a debt-to-equity ratio of 0.40. The company has a market cap of $4.85 billion, a PE ratio of 11.00 and a beta of 1.86. The firm’s 50-day simple moving average is $30.80 and its two-hundred day simple moving average is $32.56.

TG Therapeutics (NASDAQ:TGTX) last posted its quarterly earnings data on Monday, November 3rd. The biopharmaceutical company reported $2.43 EPS for the quarter, topping the consensus estimate of $0.24 by $2.19. TG Therapeutics had a net margin of 84.13% and a return on equity of 133.24%. The business had revenue of $161.71 million during the quarter, compared to the consensus estimate of $152.12 million. During the same period in the previous year, the firm posted $0.02 earnings per share. The business’s revenue for the quarter was up 92.7% compared to the same quarter last year. As a group, research analysts anticipate that TG Therapeutics, Inc. will post 0.08 earnings per share for the current fiscal year.

Insider Buying and Selling at TG Therapeutics

In other news, Director Yann Echelard sold 5,000 shares of the stock in a transaction dated Monday, November 24th. The stock was sold at an average price of $32.57, for a total value of $162,850.00. Following the transaction, the director directly owned 223,816 shares of the company’s stock, valued at approximately $7,289,687.12. This represents a 2.19% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Corporate insiders own 10.64% of the company’s stock.

Hedge Funds Weigh In On TG Therapeutics

Hedge funds and other institutional investors have recently bought and sold shares of the business. Congress Asset Management Co. acquired a new stake in TG Therapeutics during the 4th quarter valued at approximately $57,307,000. Man Group plc raised its holdings in shares of TG Therapeutics by 621.5% during the third quarter. Man Group plc now owns 1,008,462 shares of the biopharmaceutical company’s stock worth $36,431,000 after purchasing an additional 868,697 shares during the last quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS lifted its position in TG Therapeutics by 1,221.4% during the second quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS now owns 422,078 shares of the biopharmaceutical company’s stock valued at $15,191,000 after purchasing an additional 390,137 shares during the period. Goldman Sachs Group Inc. boosted its holdings in TG Therapeutics by 21.9% in the first quarter. Goldman Sachs Group Inc. now owns 1,919,416 shares of the biopharmaceutical company’s stock valued at $75,683,000 after purchasing an additional 345,059 shares during the last quarter. Finally, Marex Group plc acquired a new stake in TG Therapeutics during the 2nd quarter worth about $10,017,000. Institutional investors and hedge funds own 58.58% of the company’s stock.

About TG Therapeutics

TG Therapeutics, Inc is a clinical‐stage biopharmaceutical company headquartered in New York City that specializes in developing targeted therapies for hematological malignancies and autoimmune diseases. The company’s research strategy focuses on the modulation of B-cell biology through novel antibody and small‐molecule agents. Since its founding in 2003, TG Therapeutics has built a diversified portfolio aimed at addressing unmet medical needs in oncology and immunology.

In December 2022, TG Therapeutics achieved its first commercial milestone when ublituximab-xiiy (marketed as Briumvi® in collaboration with Biogen) received U.S.